The Beginning of the “Immunotherapy Deluge” in Multiple Myeloma

Following topline results from the phase 3 MonumenTAL-6 trial (NCT06208150), showing that teclistamab-cqyv (Tecvayli) plus talquetamab-tgvs (Talvey) reduced the risk of disease progression or death by 89% (HR, 0.11; 95% CI, 0.08-0.16; P <.0001) in relapsed/refractory multiple myeloma, additional phase 3 studies of bispecific antibody combinations in earlier lines of therapy are underway.¹

Ajay K. Nooka, MD, MPH, FACP, professor and director of the Myeloma Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine and associate director for clinical research at Winship Cancer Institute of Emory University, spoke with CancerNetwork® about what else is coming in the field. The ongoing studies assessing bispecific antibodies across different treatment settings, he said, represents the beginning of an “immunotherapy deluge.”

Additional data from the MonumenTAL-6 trial showed that teclistamab/talquetamab reduced the risk of death by 62% (HR, 0.38) compared with investigator’s choice of standard-of-care therapy.

Transcript:

CancerNetwork: Beyond this trial, MonumenTAL-6, what other potential developments or ongoing studies in multiple myeloma may further impact the paradigm?

Nooka: What we are seeing, currently, is just the beginning of this immunotherapy deluge. We talked about the bispecific antibodies currently approved: teclistamab, linvoseltamab-gcpt [Lynozyfic], and elranatamab-bcmm [Elrexfio] are the 3 BCMA bispecific antibodies, and talquetamab is the GPRC5D bispecific antibody. What we expect is similar phase 3 results in earlier phases, in maintenance, and in the frontline setting in the future with combinations of all these treatments. These are all randomized phase 3 studies that are ongoing and have completed enrollment.

[MajesTEC-3 (NCT05083169) and MonumenTAL-6] showed hazard ratios of 0.17 and 0.11, the best ever reported. In the future, do we expect these numbers to be beaten? I do not know, but I am optimistic about the good new treatments that will be available for our patients, without access issues.

References

1. Tecvayli + Talvey reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma. News release. Johnson & Johnson. July 23, 2026. Accessed July 29, 2026. https://tinyurl.com/3ee86wxk
2. Costa LJ, Bahlis NJ, Perrot A, et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;394(8):739-752. doi:10.1056/NEJMoa2514663